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The immunoregulatory activity of a nonmammalian interleukin 2 (IL-2), chicken IL-2 (chIL-2), was investigated using a DNA vaccine
against infectious bursal disease virus (IBDV) as a model. Coadministration of a plasmid encoding the VP2 gene of IBDV (pCI-VP2) and a
plasmid encoding chicken IL-2 gene (pCI-chIL-2) enhances bursal protection against both the homologous IBDV strain ZJ2000 and the
heterologous strain BC6/85 compared to administration of pCI-VP2 alone. Vaccination with pCI-VP2 alone induces low bursal protection
against ZJ2000 and only protects chickens from clinical outbreaks and mortality, but not from bursal damage caused by BC6/85. Co-
administration of the plasmid encoding the polyprotein gene of IBDV (pCI-VP2/4/3) and pCI-chIL-2 provides complete protection (15/15)
against ZJ2000 and satisfactory protection (13/15) against BC6/85. In contrast, only 10 out of 15 chickens and 6 out of 15 chickens were
protected against ZJ2000 and BC6/85, respectively, using the pCI-VP2/4/3 vaccination alone. A significant increase in the IBDV-specific
neutralizing antibody response was also observed in chickens that received pCI-VP2/4/3 plus pCI-chIL-2 as compared with those that
received the pCI-VP2/4/3 vaccination alone. By administrating different amounts of plasmid DNA, we confirmed that the pCI-chIL-2, but
not the backbone plasmid pCI, contributes to increased immunoprotection of DNA vaccine against IBDV. These results strongly indicate that
the efficacy of avian DNA vaccine can be modulated by co-administration of a plasmid encoding chIL-2.
D 2004 Elsevier Inc. All rights reserved.
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Infectious bursal disease virus (IBDV) is the causative
agent of a highly immunosuppressive disease in young
chickens. IBDV is a member of the Birnaviridae family. Its
genome consists of two segments of double-stranded RNA.
The smaller segment B (approximately 2.9 kb) encodes
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E-mail address: Jianrong.Li@umassmed.edu (J. Li).capping enzyme activities (Lombardo et al., 1999). The
larger segment A (approximately 3.3 kb) contains two
partially overlapping open reading frames (ORFs). The first
ORF encodes the nonstructural protein VP5 (17 kDa),
which has recently been shown to be dispensable for viral
replication, but important for viral pathogenesis (Mundt et
al., 1997; Yao and Vakharia, 2001). The second ORF
encodes a 110-kDa polyprotein (VP2/4/3) that is cleaved by
autoproteolysis to form the viral proteins pVP2 (48 kDa),
VP3 (32 kDa), and VP4 (28 kDa). During virus maturation,
the precursor pVP2 is further processed into mature VP2 (40
kDa) (Chevalier et al., 2002). The viral protease VP4 is
responsible for self-processing of the polyprotein (Sa´nchez
and Rodriguez, 1999). VP3 contains group-specific anti-004) 89–100
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et al., 2002). VP2 is the major host-protective immunogen
responsible for induction of neutralizing antibodies (Fahey
et al., 1989). Vaccination with VP2 or polyprotein subunit
vaccines was able to induce protection against IBDV
(Darteil et al., 1995; Fahey et al., 1989; Shaw and Davison,
2000; Tsukamoto et al., 1999, 2000). Complete protection
was conferred by vaccination with IBDVantigens expressed
by the baculovirus (Pitcovski et al., 1996; Vakharia et al.,
1994), avian herpesvirus vector (Tsukamoto et al., 2002),
and Pichia pastoris yeast (Pitcovski et al., 2003).
DNA vaccines induce both the cellular and humoral
immune responses to produce long-lasting immunity against
infectious diseases. Plasmids encoding antigens of IBDV
have been shown to be capable of inducing protective
immune responses in chickens (Chang et al., 2001, 2003;
Fodor et al., 1999; Heckert et al., 2002). However, the
efficacy of DNA vaccine is lower than that of commercial
inactivated and attenuated IBDV vaccines (Fodor et al.,
1999). Only 4 out of 20 chickens were protected from
virulent IBDV challenge even after several inoculations of
large amounts of plasmids expressing the polyprotein gene
of IBDV (Fodor et al., 1999). Furthermore, we have recently
shown that the source of the target genes (from different
IBDV strains), the eukaryotic expression vector, the
adjuvant, the delivery route, and the dosage play a role of
varying degree in influencing the efficacy of the DNA
vaccine against IBDV (Li et al., 2003).
Chemical adjuvants such as liposome and dimethylsulf-
oxide (DMSO) have been shown to enhance the efficacy of
DNA vaccination (Heckert et al., 2002). However, these
adjuvants are expensive and difficult to use in the poultry
industry. Therefore, the generation of a more effective and
economical adjuvant is required. It has been demonstrated
that the efficacy of DNA vaccines can be modulated by co-
delivery of various cytokine genes (Moore et al., 2002).
Interleukin 2 (IL-2) is perhaps the most extensively studied
of all cytokine adjuvants. Several studies have shown that
the immune responses to DNA vaccines can be enhanced
dramatically by co-administration of plasmids encoding the
mammalian IL-2 gene. Examples of this phenomena have
been found for vaccination against bovine herpesvirus 1
virus (Kuhnle et al., 1996), hepatitis C virus (Geissler et al.,
1997), hepatitis B virus (Chow et al., 1997, 1998), bovine
viral diarrhea virus (Nobiron et al., 2001), HIV (Moore et al.,
2002), foot-and-mouth disease (Wong et al., 2002), and
measles virus (Premenko-Lanier et al., 2003).
A chicken cytokine with T-cell proliferative activity was
cloned using expression library screening (Sundick and
Gill-Dixon, 1997). Sequence analysis revealed that this
cytokine has characteristics similar to both mammalian IL-2
and IL-15. Kaiser and Mariani (1999) identified this
cytokine as chIL-2, but not chicken IL-15, because the
genomic structure, promoter sequence, exon/intron struc-
ture, and synteny of the genetic location of this chicken
cytokine are more similar to those of mammalian IL-2 thanof IL-15. Recombinant chIL-2 produced in prokaryotic and
eukaryotic expression systems induces proliferation of
chicken splenocytes and thymocytes in vitro (Stepaniak
et al., 1999). Yet, the immunoregulatory effects of chIL-2 on
T cells, B cells, natural killer cells, and lymphokine-
activated killer cells in vivo, as well as in vitro, and its
feasibility as an adjuvant for avian vaccines are poorly
understood. To date, only one study has tested the use of
chIL-2 as a DNA vaccine adjuvant, and, unfortunately, it did
not have significant effect on the efficacy of DNA
vaccination against Eimeria (Min et al., 2001).
A chIL-2 cDNA has been cloned from Concanavalin A
(Con A) stimulated spleen T lymphocytes in our laboratory.
Using the highly immunosuppressive avian pathogen IBDV
as a model, we have found that chIL-2 can be successfully
used as a strong immunoenhancer of DNA vaccination.
Enhancement of the protection against both homologous
and heterologous strains of virulent IBDV was induced by
co-administration of an IBDV DNA vaccine and a plasmid
encoding chIL-2. Additionally, there was a significant
improvement in the IBDV-specific antibody response. The
discovery of an immunoenhancer function of chIL-2 reveals
a new potential approach to the development of a natural
adjuvant for avian DNA vaccines.Results
Characterization of the Xiaoshan chicken interleukin 2 gene
Based on the chIL-2 sequence published by Sundick and
Gill-Dixon (1997), two primers were designed that spanned
the coding region of chIL-2. Isolation of spleen lympho-
cytes from Xiaoshan chickens, activation by ConA,
extraction of total RNA, followed by RT-PCR resulted in
the synthesis of a 737-bp DNA fragment (data not shown).
The chIL-2 ORF was inserted into the pCI vector under
control of the CMV promoter. The sequence of the
Xiaoshan chIL-2 gene is available in GenBank at accession
number AF321056. The full-length chIL-2 cDNA is 737 bp,
encoding a 143 amino acid precursor. One to five amino
acid differences were identified in a comparison of our
sequence with the three previously published chIL-2
sequences. Xiaoshan chIL-2 shares 58.4% homology with
duck IL-2, 69.4% homology with turkey IL-2, and 21.2–
29.4% homology with mammalian IL-2. The predicted
Xiaoshan chIL-2 protein has a leader sequence composed of
22 amino acids and four conserved cysteines that allow the
formation of two intrachain disulfide bonds. In comparison,
mammalian IL-2 has only three cysteine residues that allow
for only one intrachain disulfide bond. There are four heptad
repeats with hydrophobic amino acids at positions 1 and 4,
which are presumably forming amphipathic alpha-helices.
These regions are equivalent to mammalian IL-2 helices A,
B, C, and D. In mammalian IL-2, several of the residues
important for binding to IL-2 receptors are also found in
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142(Q). Phylogenetic analysis indicates that Xiaoshan
chIL-2 is most closely related to other avian IL-2, including
those of turkey, duck, and three other chicken breeds. It
appears to have an evolutionary relationship with mamma-
lian IL-2, but it is distinct from the IL-15 family (Fig. 1).
Recombinant chIL-2 expressed in CEFs was biologically
active as quantitated using a T cell proliferation assay (data
not shown).
Enhanced immunoprotection of DNA vaccine against
homologous virulent IBDV strain ZJ2000 by
co-administration of chIL-2
At day 4 postchallenge, all of the chickens were
euthanized. As shown in Table 1, both the plasmid encoding
VP2 (pCI-VP2) and the plasmid encoding the polyprotein
gene (pCI-VP2/4/3) provided partial bursal protection
against the homologous virulent ZJ2000. However, the
efficacy of the DNA vaccine using polyprotein as the target
gene was much higher than that of the DNA vaccine using
the VP2 gene. Ten out of fifteen chickens (10/15) in the
pCI-VP2/4/3 group were protected from virus challenge. In
contrast, only 3 out of 15 chickens (3/15) in the pCI-VP2
group were protected from virus challenge.
Co-administration of chIL-2 enhanced the protective
immune response of both the VP2/4/3 and the VP2-basedFig. 1. Phylogenetic analysis of Xiaoshan chIL-2. The phylogenetic tree was con
multiple-alignment algorithm. IL-2 and IL-15 sequence data are available from thDNA vaccines. Co-administration of pCI-VP2/4/3 and pCI-
chIL-2 provided complete protection (15/15) against the
homologous virulent ZJ2000 strain, while vaccination with
pCI-VP2/4/3 alone provided partial protection (only 10 out
of 15 chickens were protected). Ten out of fifteen chickens
(10/15) were protected when the pCI-VP2 plus pCI-chIL-2
DNA vaccine was used. However, only 3 out of 15 chickens
(3/15) were protected when the pCI-VP2 DNA vaccine was
used alone. The bursa lesion scores of the chickens in co-
administration groups were significantly reduced as com-
pared to DNA vaccination alone (P b 0.05). The bursa/BW
and spleen/BW ratios of the chickens in co-administration
group had no significant difference from those of the normal
control (P N 0.05).
The chickens vaccinated with pCI, as well as those
unvaccinated but challenged, were not protected from virus
challenge and 4 out of 15 chickens died by day 4
postchallenge in both groups. These chickens showed the
typical clinical signs of IBDV, which included severe gross
bursal lesions characterized by inflammation, pale-color,
edema and point bleeding, and had significantly larger
bursas and spleens than normal chickens (P b 0.05). All of
the chickens vaccinated with pCI-chIL-2 also showed gross
bursal lesions. Although the bursal lesion scores (2.6 F
0.51) from pCI-chIL-2 group were slightly less than those
of the pCI and unvaccinated challenge control groups (3 F
0), there is no statistically significant difference among themstructed using the MEGALIGN program in LASERGENE with CLUSTAL
e GenBank database.
Table 1
Enhanced protection of the DNA vaccine against homologous virulent ZJ2000 by co-administration of the plasmid encoding chicken IL-2
Groupa Bursa lesions scoreb Average organ/BW ratioc Deadd Protectede Antigen detectionf Number of chickens
with NAg
Bursa/BW Spleen/BW
pCI-VP2 1.60 F 0.99 5.84b 2.34a 0 3/15 12/15 9/15
pCI-VP2+pCI-chIL-2 0.67 F 1.11 5.53a 2.28a 0 10/15 5/15 15/15
pCI-VP2/4/3 0.80 F 1.21 5.02a 1.94a 0 10/15 5/15 14/15
pCI-VP2/4/3+pCI-chIL-2 0 F 0 5.23a 2.02a 0 15/15 0/15 15/15
pCI-chIL-2 control 2.60 F 0.51 6.44b 2.57a 0 0/15 15/15 0/15
pCI control 3 F 0 7.25b 2.95b 4 0/15 15/15 0/15
Challenge control 3 F 0 6.91b 3.01b 4 0/15 15/15 0/15
Normal control 0 F 0 4.91a 2.11a 0 15/15 0/15 0/15
a Chickens were inoculated with 200 Ag of each DNA at 2 weeks of age and boosted 2 weeks later. All of the chickens were challenged via eye drop with 2 
104 embryo infective dose (EID50) per milliliter of virulent IBDV strain ZJ2000 at week 4 postboosting. VP2/4/3 represents the polyprotein gene.
b Bursal lesion scores were based on the system described by Shaw and Davison (2000) with some modification. Bursal lesion scores were shown as the
mean F standard deviation for 15 chickens.
c Values show the averages for 15 chickens. Average organ/BW = average organ in grams/total body weight in grams. Values within a column followed by
different lowercase letters (a or b) are significantly different from the normal control ( P b 0.05).
d Number of dead chickens at 4 day postchallenge.
e The protection rate for each challenge group was initially calculated based on gross bursal lesions and further confirmed by bursa histopathological
examination.
f Number of chickens absent of antigen detection.
g Number of chickens with NA (neutralizing antibody) response at week 4 postboosting vaccination.
J. Li et al. / Virology 329 (2004) 89–10092(P N 0.05). In addition, none of the pCI-chIL-2 vaccinated
chickens had died by day 4 postchallenge.
Enhanced cross-protection of DNA vaccine against
heterologous virulent BC6/85 by co-administration of
chIL-2
The antigenic relationship between the IBDV strain
used to vaccinate and the IBDV strain used to challenge is
very important in evaluating the efficacy of the vaccine.
Although DNA vaccination (pCI-VP2/4/3 plus pCI-chIL-2)
provided complete protection against the homologous
strain ZJ2000, protection against heterologous IBDV
strains needs to be examined. For this purpose, another
virulent strain, BC6/85, was chosen as the challenge virus.
BC6/85 is widely used in the evaluation of the efficacy of
IBDV vaccines in China.
As shown in Table 2, chickens immunized with DNA
encoding ZJ2000 VP2 (pCI-VP2) were not protected from
bursal damage by heterologous virulent BC6/85, even when
a high DNA dosage (200 Ag) and a boosting vaccination
was used for the immunization. In the pCI-VP2 group, some
of chickens did not have gross bursal lesions, but the final
histopathological examination showed that all of the bursa
from this group had histopathological lesions. However,
none of the chickens displayed clinical signs of IBDV and
none of the chickens died after challenge with BC6/85.
Thus, pCI-VP2 vaccination alone only protected chickens
from clinical outbreaks and mortality, but not from bursal
damage. Similar to the results of experiment 1, chickens
immunized with plasmid DNA encoding the VP2/4/3 (pCI-
VP2/4/3) displayed partial protection from bursal damage
by the heterologous strain BC6/85. However, only 6 out of
15 chickens (6/15) were protected, which was less than thenumber protected against the homologous ZJ2000 strain
(10/15).
Co-administration of pCI-chIL-2 significantly enhanced
the efficacy of both the pCI-VP2/4/3 and pCI-VP2 DNA
vaccines against virulent strain BC6/85 (P b 0.05). Co-
administration of pCI-VP2 and pCI-chIL-2 was able to
induce bursal protection against BC6/85. None of the
chickens challenged with BC6/85 had clinical symptoms
of IBDV, and 7 out of 15 chickens (7/15) were protected
from challenge at the bursal pathological level. However,
none of bursa were protected when only the pCI-VP2
vaccination was used. The bursa lesion scores were
significantly reduced by co-delivery with pCI-chIL-2 (P b
0.05). Thirteen out of fifteen chickens (13/15) in the pCI-
VP2/4/3 plus pCI-chIL-2 group were protected from BC6/
85 challenge, which was much higher than the number of
chickens protected in the pCI-VP2/4/3 group (6/15).
The bursa lesion scores in pCI-VP2/4/3 plus pCI-chIL-2
group were significantly less than those of pCI-VP2/4/3
group (P b 0.05). The bursa/BW and spleen/BW ratios of
chickens vaccinated with pCI-VP2/4/3 and pCI-chIL-2
were not significantly different from those of the unvacci-
nated yet unchallenged controls (P N 0.05). In contrast,
chickens vaccinated with control pCI and those that were
unvaccinated were not protected from BC6/85 challenge
and had significantly larger bursas and spleens (P b 0.05).
These chickens showed the typical clinical signs of IBDV
and had severe bursal lesions as mentioned previously. At
day 4 postchallenge, 4 out of 15 (4/15) and 5 out of 15
chickens (5/15) died in the pCI control and challenge
control groups, respectively. Chickens vaccinated with
pCI-chIL-2 alone were not protected and one chicken in
this group had died by day 4 postchallenge. The bursal
lesion score in pCI-chIL-2 group was 2.73 F 0.46, which
Table 2
Enhanced protection of DNA vaccine against heterologous virulent BC6/85 by co-administration of plasmid encoding chIL-2
Groupa Bursa lesions
score
Average organ/BW ratio Dead Protected Antigen
detection
Number of chickens
with NA
Bursa/BW Spleen/BW
pCI-VP2 2.20 F 0.93 6.30b 2.95b 0 0/15 15/15 10/15
pCI-VP2+pCI-chIL-2 1.40 F 1.41 5.58a 2.49a 0 7/15 8/15 15/15
pCI-VP2/4/3 1.20 F 1.21 5.72a 2.61a 0 6/15 9/15 15/15
pCI-VP2/4/3+pCI-chIL-2 0.20 F 0.56 5.43a 2.45a 0 13/15 2/15 15/15
pCI-chIL-2 control 2.73 F 0.46 6.56b 2.79b 1 0/15 15/15 0/15
pCI control 3 F 0 6.95b 3.75b 4 0/15 15/15 0/15
Challenge control 3 F 0 6.83b 3.29b 5 0/15 15/15 0/15
Normal control 0 F 0 5.21a 2.31a 0 15/15 0/15 0/15
a Chickens were inoculated with 200 Ag of each DNA at 2 weeks of age and boosted 2 weeks later. Each chicken was challenged via eye drop with 2  104
embryo infective dose (EID50) per milliliter of virulent IBDV strain BC6/85 at week 4 postboosting.
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challenge controls (3.0 F 0), yet they were not signifi-
cantly different (P N 0.05).
Effect of different DNA concentration on immunoprotection
of DNA vaccine
As shown in experiments 1 and 2, immunoprotection
induced by DNA vaccination against IBDV can be
improved by co-delivery of a plasmid encoding chicken
IL-2. However, the concentration of plasmid DNA used in
these experiments was not consistent. Co-injection of the
pCI-chIL-2 plasmid resulted in delivery of twice the amount
of DNA because empty backbone plasmid pCI was not co-
injected when the pCI-VP2 or pCI-VP2/4/3 plasmid was
tested. One might argue that some portion of the increased
protection in the groups receiving pCI-chIL-2 is nonspecific
due to the extra DNA administrated. To address this
question, we repeated experiment 2 but controlled the
amount of DNA in immunization by co-administrating
backbone plasmid pCI. Table 3 shows the effect of DNA
concentration on the efficacy of the DNAvaccine. Similar to
our previous finding, none of the chickens (0/12) were
protected at the bursal pathological level in the group that
received 200 Ag pCI-VP2 and 4 out of 12 chickens (4/12)Table 3
Effect of DNA amount on the efficacy of DNA vaccination
Groupa Total amount
of DNA
Bursa lesions
score
Average organ
Bursa/BW
pCI-VP2 200 Ag 1.92 F 0.67 5.80b
pCI-VP2+pCI 400 Ag 2.17 F 0.72 5.77b
pCI-VP2+pCI-chIL-2 400 Ag 1.08 F 1.08 5.24a
pCI-VP2/4/3 200 Ag 1.33 F 1.23 5.39a
pCI-VP2/4/3 + pCI 400 Ag 1.33 F 1.37 5.42a
pCI-VP2/4/3 + pCI-chIL-2 400 Ag 0.33 F 0.78 5.22a
pCI-chIL-2 200 Ag 2.75 F 0.45 6.70b
pCI-chIL-2 + pCI 400 Ag 2.58 F 0.52 6.52b
pCI control 400 Ag 3 F 0 7.01b
Challenge control / 3 F 0 7.11b
Normal control / 0 F 0 4.88a
a Chickens were inoculated with each DNA at 2 weeks of age and boosted 2 we
infective dose (EID50) per milliliter of virulent IBDV strain BC6/85 at week 4 powere protected in the group that received 200 Ag pCI-VP2/
4/3. None of the chickens (0/12) were protected in the group
that received 200 Ag each of pCI-VP2 and pCI. Only 5 out
of 12 chickens (5/12) were protected in the group that
received 200 Ag each of pCI-VP2/4/3 and pCI. Therefore,
backbone plasmid pCI does not significantly enhance the
immunoprotection of either the pCI-VP2 or the pCI-VP2/4/
3-based DNA vaccines (P N 0.05). Also, co-delivery with
pCI does not significantly reduce the bursa lesion scores
caused by virulent IBDV (P N 0.05). However, co-injection
with 200 Ag pCI-chIL-2 significantly enhanced the immu-
noprotection of the pCI-VP2 and pCI-VP2/4/3 DNA
vaccines (P b 0.05). Five out of twelve chickens (5/12)
were protected in the group that received 200 Ag each of
pCI-VP2 and pCI-chIL-2 and 10 out of 12 chickens (10/12)
were protected in the group that received 200 Ag each of
pCI-VP2/4/3 and pCI-chIL-2. Similar to our previous
findings, co-delivery of pCI-chIL-2 significantly reduced
the bursa lesion scores (P b 0.05). As for the controls, none
of chicken vaccinated with 200 Ag pCI-chIL-2, 200 Ag each
of pCI-chIL-2 and pCI, and 400 Ag pCI were protected
against challenge with IBDV. Therefore, the increased
immunoprotection is indeed due to the co-injection of
plasmid encoding chIL-2, and not due to the increased
amount of DNA (pCI) administrated. Co-injection with/BW ratio Dead Protected Antigen
detection
Number of chickens
with NA
Spleen/BW
2.74b 0 0/12 12/12 7/12
2.84b 0 0/12 12/12 6/12
2.30a 0 5/12 7/12 12/12
2.23a 0 4/12 8/12 12/12
2.34a 0 5/12 7/12 12/12
2.24a 0 10/12 2/12 12/12
2.89b 2 0/12 12/12 0/12
3.02b 1 0/12 12/12 0/12
3.22b 3 0/12 12/12 0/12
3.30b 3 0/12 12/12 0/12
2.10a 0 12/12 0/12 0/12
eks later. Each chicken was challenged via eye drop with 2  104 embryo
stboosting.
Fig. 2. Enhanced antibody response of DNA vaccine by co-administration
of plasmid encoding chIL-2. Co-administration of 200 Ag of pCI–chIL-2
significantly enhances the antibody response of vaccination with 200 Ag of
pCI-VP2 (a) and 200 Ag of pCI-VP2/4/3 (b). Co-administration of 200 Ag
of plasmid pCI does not significantly enhance the antibody response of
vaccination with 200 Ag pCI-VP2/4/3 (c). Serum was collected weekly
from 15 chickens in each group. Antibody was detected by the virus
neutralization (VN) assay. The VN titer was determined by the system
described by Reed and Muench (1938). Values are shown as Geometric
Mean Titer (GMT) F standard error.
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efficacy of DNA vaccination (P N 0.05).
Reduction of IBDVantigen replication in bursa of Fabricius
by co-administration of chIL-2
To detect whether DNA vaccination can prevent virus
replication in bursa of Fabricius, bursa section from each
group was subjected to examination of the presence of
IBDV antigens in bursa of Fabricius by an immunofluor-
escence assay at day 4 after challenge with virulent IBDV.
As shown in Tables 1–3, co-administration of either pCI-
VP2/4/3 or pCI-VP2 with pCI-chIL-2 reduced the IBDV
antigen positive ratio as compared to ratios seen when the
pCI-VP2/4/3 or pCI-VP2 vaccination alone was used. This
indicates that chIL-2 was able to enhance the ability of the
DNA vaccine to prevent IBDV replication in the bursa
postchallenge. However, co-administration of either pCI-
VP2/4/3 or pCI-VP2 with backbone plasmid pCI did not
reduce the IBDVantigen-positive ratio as compared to DNA
vaccination alone (Table 3). All of the chickens in the pCI-
chIL-2, pCI, and challenge controls were positive for
antigen. No antigen was detected in any of the chickens in
the normal control group.
Enhanced antibody response of DNA vaccine by
co-administration of pCI-chIL-2
Although VP2 is the major host–protective antigen
responsible for the induction of neutralizing antibodies,
DNA encoding the VP2 gene was not efficient at eliciting an
antibody response. Even at week 4 postboosting vaccina-
tion, only 9–10 out of 15 chickens had low-level neutraliz-
ing antibody responses (Tables 1 and 2; Fig. 2a).
Interestingly, neutralizing antibody was detected in most
chickens vaccinated with pCI-VP2 plus pCI-chIL-2 at week
2 postboosting vaccination. At week 4 postboosting, all of
the chickens had an antibody response in the co-admin-
istration group, and the titer was significantly higher than
that of the pCI-VP2 group (P b 0.05) (Fig. 2a). There was
no specific IBDV antibody response detected in chickens
vaccinated with pCI or pCI-chIL-2 and the unvaccinated
unchallenged control groups.
Fig. 2b indicates that the neutralizing antibody response
induced by the pCI-VP2/4/3 DNA vaccine can be
modulated by co-administration with pCI-chIL-2. Most
chickens immunized with pCI-VP2/4/3 can produce
neutralizing antibody, but it takes an extended amount of
time to develop this response. At week 2 postprimary
vaccination, the antibody levels of chickens in the pCI-
VP2/4/3 group were undetectable, even when 200 Ag of
DNA was used for vaccination. However, most of the
chickens in the co-administration group had detectable
antibody response at this time point, indicating that an
antibody response can be induced earlier by co-injection
with pCI-chIL-2. After boosting with pCI-VP2/4/3, most
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ally increased in amount, indicating that a secondary
immune response had been induced by the DNA vaccine.
On contrast, after boosting with pCI-VP2/4/3 and pCI-
chIL-2, the antibody titers increased significantly (P b
0.05). Throughout the experiment, the antibody titer of the
co-administration group was significantly higher than that
of the pCI-VP2/4/3 group (P b 0.05). Chickens vaccinated
with either pCI or pCI-chIL-2 and the normal control had
undetectable antibody levels.
To address the possibility that DNA concentration plays
a role in enhancing antibody responses, the experiment was
controlled by co-delivery with backbone plasmid pCI in
immunization. At week 4 postboosting vaccination, 7 out of
12 chickens had antibody responses in the pCI-VP2 group,
and 6 out of 12 chickens had the antibody response in the
pCI-VP2 plus pCI group (Table 3). However, all of the
chickens in the pCI-VP2 plus pCI-chIL-2 group developed
antibody responses. As shown in Fig. 2c, co-delivery of the
backbone plasmid does not significantly enhance the anti-
body response of pCI-VP2/4/3 (P N 0.05). However, the
antibody response of the group that received 200 Ag each of
pCI-VP2/4/3 and pCI-chIL-2 was significantly higher than
that of the group that received 200 Ag of pCI-VP2/4/3 alone
(P b 0.05). This further confirms that the enhanced
antibody response is due to the co-injection of plasmid
encoding chIL-2, not due to the increased amount of DNA
(pCI) administrated.Discussion
Interleukin 2 (IL-2) is a very important cytokine
produced by activated T lymphocytes that exerts immu-
noregulatory effects on a variety of immune cells,
including T cells, activated B cells, natural killer cells,
and lymphokine-activated killer cells. In addition to acting
as an immunoregulator, mammalian interleukin 2 (IL-2)
has been shown to be a strong adjuvant for DNA vaccines
(Moore et al., 2002). The chIL-2 gene was the first cloned
nonmammalian IL-2 gene and limited information is
available as to the ability of chIL-2 to function as an
adjuvant for avian DNA vaccines. Many immunosuppres-
sive avian pathogens such as IBDV (Wu et al., 2000),
Marek’s disease virus (Xing and Schat, 2000), Newcastle
disease virus (Thiagarajan et al., 1999), chicken anemia
virus (Markowski-Grimsrud and Schat, 2003), and Eimeria
tenella (Chio and Lillehoj, 2000) interfere with the
induction of or cause abnormal production of chIL-2 in
vivo. This suggests that chIL-2 may be important for
control of these diseases. IBDV is a good disease model in
which to study the immunoregulatory function of chIL-2,
not only because it is a highly contagious immunosup-
pressive disease that depletes B cell populations within the
bursa of Fabricius, but also because both the humoral and
cell-mediated immune response are important in control ofthe disease. In this study, we have found that the
immunogenicity of a DNA vaccine against IBDV can be
improved by co-delivery of a plasmid encoding chIL-2.
The potential roles of chIL-2 in the IBDV DNA vaccine
include (1) enhancement of immunoprotection by IBDV
DNA vaccine against both homologous and heterologous
virulent strains of IBDV; (2) reduction of IBDV antigen
replication in the bursa of Fabricius after virulent IBDV
challenge; and (3) improvement of the specific IBDV
neutralizing antibody response induced by the DNA
vaccine. We also showed that the pCI-chIL-2, but not
the backbone plasmid pCI, contributes to increased
immunogenicity of DNA vaccine against IBDV. In
addition, chIL-2 has many distinct advantages over
conventional adjuvants (such as liposome, DMSO), includ-
ing biological stability and safety. Our work indicates that
chIL-2 is a promising cytokine adjuvant for IBDV DNA
vaccines and perhaps other avian pathogen DNA vaccines
in the future.
The major host-protective antigen of IBDV, VP2,
contains at least three independent epitopes responsible
for the induction of neutralizing antibodies. It has been
shown that the ability of VP2-based subunit vaccine to
protect against virulent IBDV is highly dependent on the
conformation and structure of the antigenic sites. VP2
expressed in E. coli was not efficient in eliciting virus-
neutralizing antibody (Jagadish et al., 1988). Denatured
VP2 does not induce protection in chickens (Fahey et al.,
1989), and denatured and renatured VP2 is also unable to
induce neutralizing antibodies in chickens (O¨ppling et al.,
1991). We and other researchers (Fodor et al., 1999) have
shown that chickens vaccinated with a plasmid encoding
the VP2 gene lack a neutralizing antibody response. Only
3 out of 15 chickens were protected from bursal damage
after challenge with the homologous strain ZJ2000. None
of the chickens were protected from bursal damage by the
heterologous strain BC6/85 although a large amount of
DNA was administered. Thus, a VP2-based DNA vaccine
can only protect chickens from clinical outbreaks and
mortality, but not from bursal damage. The low efficacy of
the VP2-based DNA vaccine may be due to conforma-
tional defects in its epitopes and low immunogenicity. In
contrast, most of the chickens vaccinated with pCI-VP2
plus pCI-chIL-2 had detectable antibody responses, and
some of the chickens were protected from bursal damage
by both ZJ2000 and BC6/85. One possible explanation for
this result is that the expressed VP2 protein triggers a
weak immune response in vivo that is not strong enough to
protect against virulent IBDV infection, but can be
amplified by the expression of chIL-2. Therefore, a
stronger antibody response and a higher level of protection
were observed when chickens were co-vaccinated with
both pCI-VP2 and pCI-chIL-2.
The polyprotein precursor (VP2/4/3) is proteolytically
processed to give rise to mature VP2, VP3, and VP4
polypeptides, generating the natural conformation of multi-
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the IBDV polyprotein in cells may generate virus-like
particles (VLP) in the form of close-packed paracrystalline
arrays, which are very similar to authentic IBDV particles in
shape and size, as previously shown by electron microscopy,
and are specifically recognized by anti-IBDV antibodies
(Ferna´ndez-Arias et al., 1998; Martinez-Torrecuadrada et al.,
2003). Therefore, it is not surprising that the immunogenic
response induced by the plasmid encoding the polyprotein
was much higher than that induced by the plasmid encoding
the VP2 gene of IBDV. Our data indicates that the plasmid
encoding the polyprotein gene provides good protection
against the homologous strain ZJ2000 (Table 1), but not
against the heterologous strain BC6/85 (Table 2). Most
importantly, co-administration of 200 Ag each of pCI-VP2/
4/3 and pCI-chIL-2 provides complete protection against the
homologous virulent ZJ2000 strain (Table 1) and enhances
protection against the heterologous virulent BC6/85 strain
(Table 2). In accordance with the experimental challenge
assay, the antibody response induced by co-administration
of pCI-VP2/4/3 plus pCI-chIL-2 was significantly higher
than that induced by vaccination with pCI-VP2/4/3 alone
(P b 0.05). Also, the production of antibody induced by co-
administration of the plasmids began 1–2 weeks earlier than
when pCI-VP2/4/3 was administrated alone. Namely, the
antibody silent period becomes shorter when chIL-2 is used
as an adjuvant. This could be very helpful in the control of
infection soon after chickens are exposed to IBDV.
To address whether the DNA concentration affects the
efficacy of DNA vaccine, chickens were vaccinated with
equal amounts of DNA by co-injection with either the
empty backbone plasmid pCI or pCI-chIL-2. The results
showed that the backbone plasmid pCI does not
significantly enhance the efficacy of either the VP2 or
VP2/4/3-based DNA vaccines (P N 0.05) (Table 3). In
contrast, co-injection with pCI-chIL-2 significantly enhan-
ces immunoprotection and the antibody response (P b
0.05) (Tables 1–3). Therefore, the increased efficacy is
indeed due to the use of pCI-chIL-2, but not the extra
DNA of the pCI vector itself. It is well known that CpG
oligodeoxynucleotide (ODN) can enhance the immunoge-
nicity of DNA vaccines (Rankin et al., 2001). However, no
evidence has shown that the backbone plasmid pCI vector
can directly function as a CpG ODN. A recent study has
shown that efficacy of DNA vaccines against IBDV was
enhanced by co-administration with CpG ODN (Wang
et al., 2003). The CpG ODNs were synthesized artificially
and composed of a 20–30-bp nucleotide sequence con-
taining potential stimulatory motifs, similar to those widely
used in other studies investigating the adjuvant effect of
CpG (Rankin et al., 2001).
Recent studies have shown that recombinant chIL-2
has functions similar to those of mammalian IL-2 (Kaiser
and Mariani, 1999; Stepaniak et al., 1999). IL-2 is known
to promote a Th1-type response (Chow et al., 1998) and
may be most useful as a vaccine adjuvant in diseaseswhere cell-mediated immunity plays an important role in
protection against pathogens. Although the humoral
immune response is important for protecting chickens
against IBDV infection, there is increasing evidence that
the cellular immune response is also critical. In this
study, we have demonstrated that vaccination with pCI-
VP2 is able to protect chickens from clinical outbreaks
and mortality caused by challenge with either the ZJ2000
or BC6/85 strain of IBDV. Additionally, it induced
protection against bursal damage caused by the ZJ2000
strain although half of the immunized chickens lacked an
antibody response. Furthermore, Yeh et al. (2002) found
that cell-mediated immunity alone can protect birds
against virulent IBDV in the absence of antibody.
Similarly, it has been reported that recombinant fowlpox
VP2 vaccine induced protection in the absence of
detectable serum antibodies (Shaw and Davison, 2000).
In addition, we found that complete protection is obtained
when pCI-chIL-2 is used as an adjuvant. Rautenschlein et
al. (2002a, 2002b) demonstrated that T cells were
necessary to achieve full protection against virulent
IBDV. Thus, co-administration of pCI-VP2/4/3 and pCI-
chIL-2 possibly induces a T cell response that results in a
full protection. Co-administration of pCI-VP2 plus pCI-
chIL-2 provides the same level of bursal protection
against strain ZJ2000 (Table 1) and even better bursal
protection against BC6/85 (Table 2) than administration
of pCI-VP2/4/3 alone. However, the antibody titer of the
pCI-VP2 plus pCI-chIL-2 group was much lower than
that of the pCI-VP2/4/3 group (Figs. 2a and b). The lack
of correlation between protection and antibody further
supports the possibility that a cell-mediated immune
response is involved in protection against IBDV. In
addition, it has been reported that subcutaneous injection
of chickens with a plasmid expressing IL-2 enhances T
cell and natural killer cell responses (Chio and Lillehoj,
2000). ChIL-2 also directly induces activation and
proliferation of chicken T cells in vivo (Hilton et al.,
2002). Overall, the above observations strongly indicate
that chIL-2 can enhance not only the humoral immune
response, but also the cell-mediated response triggered by
DNA vaccination.
Other functions of chIL-2 may also play a role in
enhancing the immunogenicity of IBDV DNA vaccines.
Recently, recombinant chIL-2 has been found to signifi-
cantly increase the phagocytosis and bactericidal activity of
heterophils, which are the avian equivalent of neutrophils
and function as professional phagocytes to aid in regulation
of innate host defenses (Kogut et al., 2002). ChIL-2 also
enhances respiratory burst in response to antigen stimulation
(Kogut et al., 2002). This indicates that chIL-2 may be very
important for disease prevention and resistance to pathogen
infections. It is also possible that chIL-2 may have other
potential functions such as immunotherapy, which has been
well documented in mammalian IL-2. During the IBDV
challenge test, we also found that chickens vaccinated with
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those vaccinated with pCI or unvaccinated but challenged
controls. The adjuvant activity of chIL-2 may be also
involved in promoting the avian immune system to produce
other cytokines such as chicken IFN-a and IFN-g, which
also function as immunoenhancers. It has been shown that
co-administration of antigen and IFN-g enhances antibody
responses in chickens and co-injection of the IFN-g gene
with an Eimeria DNA vaccine improves protective immun-
ity against coccidiosis (Min et al., 2001).
Recently, antigenic variant and very virulent (vvIBDV)
of IBDV have emerged and caused considerable economic
losses to the poultry industry around the world (Darteil et
al., 1995; Ismail et al., 1990; Tsukamoto et al., 1999; Yu et
al., 2000, 2001). Traditional inactivated or attenuated
vaccines cannot provide sufficient protection against these
variants and vvIBDV (Tsukamoto et al., 2000; Yeh et al.,
2002; Yu et al., 2000). In an experimental challenge assay,
it was shown that the protection of IBDV vaccine against
virulent IBDV was highly dependent on the antigenic
correlation value between vaccinated virus and challenge
virus (Shaw and Davison, 2000). DNA vaccination may
overcome these defects because it is able to induce both
humoral and cell-mediated immunity. Although the anti-
genic correlation value between IBDV strains ZJ2000 and
BC6/85 is unknown at molecular level, the strain ZJ2000
polyprotein gene-based DNA vaccine provided strong
protection against BC6/85, indicating that cross-protection
was induced by DNA vaccination. Our preliminary data
also indicates that co-expression of the polyprotein of
IBDV and chIL-2 provides protection against virulent
IBDV strain ZJ991, which is an antigenic variant strain
isolated in China (our unpublished data). These observa-
tions suggest that co-administration of DNA vaccines and
chIL-2 could potentially be used as a standard vaccination
method.
In conclusion, chIL-2 is a strong immunoregulator of the
IBDV DNA vaccine. It enhances the IBDV-specific anti-
body response and provides protection against challenge
with homologous and heterologous virulent IBDV. Further
research is needed to test chIL-2 as an adjuvant for use with
DNA vaccination against antigenic variant IBDV and
vvIBDV. In addition, it will be necessary to determine if
chIL-2 has similar adjuvant functions when co-administered
with other avian viral DNA vaccines.Materials and methods
Animals
The Xiaoshan chicken is a local Chinese breed that was
purchased from Xiaoshan Chicken Farm, Xiaoshan, Zhe-
jiang, P.R. China. Specific pathogen-free (SPF) eggs and
chickens were purchased from the Experimental SPF
Chicken Farm, Shandong Institute of Poultry Science,Shandong, P.R. China. Chickens were hatched and raised
in a disease containment building, and then moved into
isolators before inoculation. The flexible plastic isolators
were supplied with filtered intake and exhaust air.
Virus
ZJ2000 is a virulent IBDV strain that was originally
isolated from a commercial layer flock in Hangzhou,
Zhejiang, P.R. China. This virus strain was adapted in
chicken embryo fibroblasts (CEFs) and used for the virus-
serum neutralization test. BC6/85, another virulent IBDV
strain, was used for the virus challenge studies and was
purchased from China National Institute for Supervision of
Veterinary Pharmaceuticals, Beijing, P.R. China. Both
ZJ2000 and BC6/85 are highly virulent, causing severe
bursal lesions characterized by inflammation, edema, and
point bleeding at day 4 postchallenge.
Construction of DNA vaccine expression plasmids
Construction of the IBDV-ZJ2000 VP2 and VP2/4/3
recombinant pCI (Promega) expression plasmids has been
described previously (Li et al., 2003). The VP2/4/3 was
released from the pGEM-T-Easy vector by EcoRI and KpnI
digestion and ligated into the pCI vector cut by the same
enzymes, resulting in construction of the pCI-VP2/4/3
plasmid. The VP2 was released from pGEM-T-Easy vector
by EcoRI and XbaI digestion and ligated into pCI at the
same sites, resulting in construction of the pCI-VP2
plasmid. Large-scale extraction and purification of the
plasmids were performed as previously described (Li et
al., 2003).
Cloning and identification of chicken interleukin 2 cDNA
Spleens from 4-week-old Xiaoshan chickens were
collected aseptically into RPMI 1640 medium (Invitro-
gen). Spleen tissue was minced using a pair of scissors
and passed through a steel mesh to obtain a homogeneous
cell suspension. The cells were pelleted by centrifugation
at 1000  g for 20 min at 4 8C and washed twice in
RPMI 1640 medium. After assessment of cell viability by
Trypan blue dye exclusion technique, the cells were
resuspended at a concentration of 107cells/ml in RPMI
1640 medium (containing 1% l-glutamine, 2 mg/ml
bovine serum albumin, 1 U/ml penicillin, and 1 Ag/ml
streptomycin). The cells were cultured in six-well plates
and stimulated with ConA at a final concentration of 10
Ag/ml at 40 8C in a humidified atmosphere with 5% CO2.
The cells were harvested, and the mRNA was isolated by
Trizol reagent (Invitrogen) at 6, 12, 18, and 24 h after
ConA stimulation.
To obtain the full coding sequence of chIL-2, primer P1
(5V-ATGATGTGCAAAGTACTGATC-3V) and primer P2 (5V-
TTATTTTTGCAGATATCTCACAAAG-3V) were designed
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Gill-Dixon (1997). First-strand cDNA synthesis was
performed for 90 min at 42 8C in a 20 Al volume
containing 5 pmol of primer P2, 200 U Superscript II
(Invitrogen), and 500 ng mRNA. The cDNA fragment was
amplified using the Expand High Fidelity PCR System
(Roche Diagnostics, Indianapolis, IN). The optimal reac-
tion mixture contained 2 Al of template, 5 Al of 1 
Expand High Fidelity PCR buffer, 50 AM of each dNTP,
0.5 pM of each primer, and 2.5 mM MgCl2. The
amplification program included 4 min at 94 8C for
predenaturation, followed by 30 cycles of 45 s at 94 8C
for denaturation, 45 s at 55 8C for annealing, 1 min at
72 8C for elongation, and finally a single 3-min incubation
at 72 8C for prolonged elongation. The desired 737-bp
fragment was cloned into the pGEM-T Easy Vector by the
T-A cloning kit (Promega). Finally, the 432-bp fragment
containing the whole chIL-2 ORF was amplified by PCR
with primers P3 (5V CGGAATTCATGATGTGCAA-
AGTACTGATC 3V) and P4 (5V TTGTCGACTTACACCA-
CCACCACCACCACTTTTTGCAGATATCTCACAAA
3V), digested with EcoRI and SalI, and cloned into the pCI
vector at the same sites, resulting in the construction of the
pCI-chIL-2 plasmid. The correct orientation of the insert
was verified by enzyme digestion and sequencing.
Animal immunization and experimental challenges
Experiment 1: challenge with homologous IBDV virulent
strain ZJ2000
Fourteen-day-old SPF chickens were randomly divided
into eight groups with 15 chickens per group. Chickens in
group 1 received 200 Ag of pCI-VP2. Group 2 received
200 Ag each of pCI-VP2 and pCI-chIL-2. Group 3
received 200 Ag of pCI-VP2/4/3. Group 4 received 200
Ag each of pCI-VP2/4/3 and pCI-chIL-2. Group 5 received
200 Ag of pCI-chIL-2. Group 6 received 200 Ag of pCI.
Group 7 served as the unvaccinated challenge control
(challenge control), and Group 8 served as the unvacci-
nated yet unchallenged control (normal control). All of the
chickens were immunized intramuscularly at 14 days of
age. After 2 weeks, the chickens were boosted with DNA
vaccines using the same route and dosage. At week 4
postboost, 15 chickens from each group were challenged
with homologous virulent IBDV strain ZJ2000. The
chickens were observed every 6 h to determine if any
clinical signs of IBDV emerged and to remove the dead
chickens from the isolators. All of the chickens challenged
with IBDV were euthanized at 4 days postchallenge.
Bursas and spleens were removed and weighed, and the
mean organ/body weight (BW) ratio was determined
according to Ismail et al. (1990) using the following
formula: (organ weight in grams  1000)/BW in grams.
The protection rate for each challenge group was initially
calculated based on gross bursal lesions and further
confirmed by bursa histopathological examination. Chick-ens with complete absence of histological lesions were
considered to be protected against IBDV challenge. Thin
sections of bursa were also subjected to an immunofluor-
escence assay for antigen detection.
Experiment 2: challenge with heterologous virulent BC6/85
The experimental design, DNA vaccination, virus chal-
lenge, and evaluation of protection procedures were
identical to those used in experiment 1 except that the
challenge virus was changed to the virulent IBDV strain
BC6/85.
Experiment 3: effect of DNA concentration on the efficacy of
DNA vaccination
Fourteen-day-old SPF chickens were randomly divided
into 11 groups with 15 chickens per group. Group 1
received 200 Ag of pCI-VP2. Group 2 received 200 Ag
each of pCI-VP2 and backbone plasmid pCI. Group 3
received 200 Ag each of pCI-VP2 and pCI-chIL-2. Group
4 received 200 Ag of pCI-VP2/4/3. Group 5 received 200
Ag each of pCI-VP2/4/3 and pCI. Group 6 received 200 Ag
each of pCI-VP2/4/3 and pCI-chIL-2. Group 7 received
200 Ag of pCI-chIL-2. Group 8 received 200 Ag each of
pCI-chIL-2 and pCI. Group 9 received 400 Ag of pCI.
Group 10 served as the challenge control, and Group 11
served as the normal control. The vaccination procedure
was the same as that used in experiment 1. At week 4
postboosting, 12 chickens from each group were chal-
lenged with BC6/85. The protection ratio was evaluated as
described in experiment 1.
Virus neutralization assay for virus-specific antibodies
Blood samples were taken from 15 chickens selected
randomly from each group at 1-week intervals after
immunization. Serum samples were prepared, inactivated
for 30 min at 56 8C, and stored at 20 8C. The virus
neutralization (VN) assay was carried out by varying the
serum levels with a constant virus concentration on primary
SPF CEFs as previously described (Tsai and Saif, 1992).
Briefly, serial 2-fold dilutions of each serum sample were
prepared in MEM, neutralized with 100 TCID50 of the
IBDV strain ZJ2000, and transferred onto monolayers of
CEFs cultured in 96-well plates. The VN titer was
determined from the cytopathological effect (CPE) using
the system described by Reed and Muench (1938). The
geometric mean titer (GMT) of antibody was calculated for
each group.
Antigen detection of bursa of Fabricius
The immunofluorescence assay was used to determine
the presence of IBDVantigens in the bursa of Fabricius after
virus challenge. Each bursa was frozen and then sectioned
in a cryostat at 6-mm thickness. The sections were fixed in
acetone/methanol (1:1) for 5 min at room temperature,
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then stained with a goat anti-mouse FITC-labeled IgG
(Invitrogen). The sections were examined with a fluorescent
microscope. Bursa sections completely absent of fluores-
cence were considered negative.
Histopathological examination of bursal samples
All of the bursal samples were fixed in 10% form-
aldehyde and embedded with wax. Thin sections were
prepared for hematoxylin–eosin (HE) staining and histo-
pathological examination of bursal lesions. The lesions on
bursa of Fabricius were scored using the system developed
by Shaw and Davison (2000) with the following modifica-
tion: score 0—no bursal damage or lesions in any follicle,
clear demarcation of medulla and cortex; score 1—mild
necrosis and mild lymphocyte depletion of a few follicles
with the overall bursal architecture maintained; score 2—
moderate atrophy or lymphocyte depletion in 1/3 to 1/2 of
the follicles, aggregation of heterophils, macrophages, and
hyperplasia of epithelial reticular cells with some vacuole-
like structures; score 3—more than 1/2 of follicles with
severe necrosis, atrophy, and lymphocyte depletion, and loss
of the outline of follicular architecture such that it is
replaced by proliferated connective tissue and fibroplasias.
Bursal lesion score of each group was shown as the mean F
standard deviation.
Statistical analysis
The average organ/body weight ratios of the challenged
groups were compared with those of the control groups for
statistical significance using analysis of variance followed
by Fisher’s least significance difference. Antibody titers and
bursal lesion scores were analyzed using the SPSS 8.0
software (SPSS Inc. Chicago, IL, USA) to determine the
differences among groups.Acknowledgments
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